{Reference Type}: Journal Article
{Title}: HUS and the case for complement.
{Author}: Conway EM;
{Journal}: Blood
{Volume}: 126
{Issue}: 18
{Year}: Oct 2015 29
{Factor}: 25.476
{DOI}: 10.1182/blood-2015-03-569277
{Abstract}: Hemolytic-uremic syndrome (HUS) is a thrombotic microangiopathy that is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. Excess complement activation underlies atypical HUS and is evident in Shiga toxin-induced HUS (STEC-HUS). This Spotlight focuses on new knowledge of the role of Escherichia coli-derived toxins and polyphosphate in modulating complement and coagulation, and how they affect disease progression and response to treatment. Such new insights may impact on current and future choices of therapies for STEC-HUS.